Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Enters $269 Million Agreement for BioAtla's CTLA-4 Inhibitor

publication date: Apr 9, 2019

Beijing's BeiGene in-licensed a conditionally activated inhibitor of CTLA-4 from BioAtla of San Diego in a $269 million agreement. The two companies will test BA3071 (CAB-CTLA-4) as a monotherapy and in combination with BeiGene's PD-1 candidate, tislelizumab. BioAtla will receive $20 million up front and is eligible for undisclosed early clinical milestones, plus $249 million in subsequent milestones. BeiGene will own a co-exclusive license with BioAtla to develop and manufacture the candidate, along with an exclusive global commercialization license. More details....

Stock Symbols: (NSDQ: BGNE; HK: 6160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.